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1. Introduction
1.1. Epilepsy and oxidative stress
Epilepsy is a common chronic neurological disorder with a prevalence of 0, 4 – 1 % of the
general population [1]. The highest incidence rates are in children and elderly. Epilepsy is
characterized by recurrent unprovoked seizures, generalized or focal. The epileptic seizure is
a clinical manifestation of transient excessive and hyper synchronous activity of neurones in
the brain. It may include alterations of consciousness, motor or autonomic components or
subjective sensory or psychic phenomena. An epilepsy syndrome is a complexity of signs and
symptoms defining a unique condition. One of the most common syndromes is Juvenile
myoclonic epilepsy accounting for up to 10% of all epilepsies [2].
Etiology of epilepsy in the majority is not identified [3]. Genetic defect or structural-metabolic
disorder of the brain may be the cause of some chronic seizures. The commonest acquired
causes of epilepsy include vascular diseases, tumours, trauma, and infections of the central
nervous system [2]. However, the mechanisms of epileptogenesis are not well understood.
Experimental and human studies suggested that the homeostasis of trace elements and
membrane lipid peroxidation due to increase of free radicals or decreased of antioxidant
defence mechanisms have been causally involved in some forms of epilepsies. They were
directly or indirectly implicated as taking part in the pathophysiology of neuronal excitability,
neuronal excitotoxicity, seizure recurrence and its resistance to treatment with antiepileptic
drugs [4].
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Oxidative stress is a common pathogenic mechanism in neurodegenerative disorders. The
central nervous system is particularly susceptible to reactive oxygen species (ROS) due to high
oxygen demands of the brain, low concentration of endogenous antioxidants and concomitant
accumulation of reactive iron. Furthermore, the abundance of polyunsaturated fatty acids and
excess of predominant neurotransmitter glutamate, favour cell toxicity [5]. ROS can activate a
self-accelerating vicious cycle leading to mitochondrial damage and neuronal cell death [6].
In epilepsy, the oxidative/antioxidative balance can have a role in both seizure controls and
side effects of often life-long pharmacotherapy.
2. Pharmacotherapy of epilepsy-Valproic acid
There are a large range of antiepileptic drugs with different mechanisms of action, pharma‐
cokinetics, pharmacology, and important side effects. Pharmacotherapy of epilepsy is symp‐
tomatic.
Valproic acid (VPA) which is an eight-carbon branched-chain fatty acid, is one of the most
widely used effective antiepileptic drugs. The main mechanism of the action includes a
blockade of sodium channels, activating calcium dependent potassium conductance and
GABAergic effect [7]. VPA is metabolized by microsomal glucuronide conjugation, mitochon‐
drial beta-oxidation and cytochrome P450-dependent omega-, (omega-1)-and (omega-2)-
oxidation [8]. Therefore, an involvement of lipid peroxidation seems to be probable during
pharmacotherapy with VPA.
Serious side effects are relatively rare but include fatal hepatotoxicity and acute haemorrhag‐
ic pancreatitis. They occur mainly in children on polypharmacy and those with organic brain
disease. Hyperammonaemic encephalopathy has been reported in patients with urea cycle
disorder. Benign elevation of liver enzymes is common during valproate therapy and dose
depended. Thrombocytopenia and other haematological abnormalities should be control‐
led. Other troublesome adverse effects are weight gain, gastrointestinal disturbances, hair
loss  and  tremors.  Hormonal  disturbances  with  polycystic  ovary  syndrome  and  risk  of
teratogenicity, including a 1 to 3% risk of neural tube defects, make the use of VPA in some
women undesirable [7].
In numerous studies there was found to be an imbalance in oxidative status of the patient with
epilepsy treated with VPA [9].
3. Role of trace elements and antioxidant enzymes in epilepsy
3.1. Iron
In several neurodegenerative diseases, iron accumulates in brain tissues. Since post-mortem
examinations cannot distinguish whether iron accumulation is a cause or consequence of brain
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damage, it is necessary to manipulate iron to assess its causal role. In the animal model of
epilepsy, iron supplementation increased damage in various brain regions, and a tight
relationship between iron and zinc in micro gliosis was found [10]. In general, iron is kept safe
by binding itself to protein; transported in form of transferrin-bound iron or stored in form of
ferritin. The liberation of free iron can augment generation of active free radicals and it appears
to play a crucial role in the posttraumatic epilepsy [11]. Iron deposition results in tissue damage
by either directly damaging cells or changing the cellular environment so that it is more
susceptible to toxins or other pathologic processes. On the other hand, iron is a cofactor of
catalase (CAT), which plays a role in antioxidant defence systems by catalysing the decom‐
position of hydrogen peroxide. The proper balance of iron without excessive supplementation
is very important for oxidant status.
The surrogate markers of iron status may be non-transferrin bound iron (NTBI). There was
found an increase in NTBI in patients treated due to epilepsy with VPA [12].
3.2. Selenium, cooper, zinc
The trace elements selenium (Se), cooper (Cu) and zinc (Zn) are important cofactors of
antioxidant enzymes such as superoxide dismutase (Cu-SOD, Zn-SOD), glutathione peroxid‐
ise (GPX) as well as protein with antioxidant properties, ceruloplasmin (CRL, copper-binding
protein). SOD and GPX play a predominant role as free radical scavengers in the brain tissue,
whilst CAT is deficient [13]. SOD and GPX are also important for detoxification of xenobiotics,
and may be involved in the oxidative injury caused by antiepileptic drugs [14].
Results of various studies on trace elements levels and activities of main antioxidant enzymes
during pharmacotherapy of epilepsy are conflicting. A selected bias of patients and different
laboratory methods might be responsible, as well as the influence of lifestyle with consumption
of natural antioxidants or their supplementation [4, 15, 16].
A decrease in the trace elements selenium and copper was reported in epileptic patients
receiving sodium valproate [17]. One of the main selenium status marker is plasma glutathione
peroxidise (GPX3). The product of plasma SOD (pSOD) activity, H2O2, is the major substrates
for GPX3. An involvement of lipid peroxidation seems to be probable and the elevated activity
of pSOD in some studies may be explained by this induction. Significant effects of duration of
VPA therapy, activity of seizures and gender were found on Zn, pSOD, and erythrocyte SOD
(eSOD) levels [4, 9]. Also in prospective studies [18, 19] were reported increased levels of eSOD
in epileptic children after implementation of VPA treatment. Some other authors did not find
a significant difference in enzyme activity or even a reduced level of pSOD was found in young
people with epilepsy treated using valproate [20].
pSOD is a sensitive index of Cu status, while plasma Cu is not a reliable marker of copper
status [21]. Zinc supplements can decrease SOD activity, primarily due to the antagonistic
relationship between high zinc intakes and copper absorption [22, 23]. A few authors reported
lower or normal Zn concentrations in persons with epilepsy [24, 25]
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4. Carnitine and cellular energy
L-carnitine is the key factor in mitochondrial beta oxidation of fatty acids for the generation
of metabolic energy. Apart from carrying the long-chain fatty acids into the mitochondrial
matrix, it takes part in transporting from peroxysomes into mitochondria the products of
oxidation of very long-chain fatty acids and in removing from mitochondria medium and
short-chain fatty acids, which can be toxic at a high level. As a donor of acetyl group, it
participates in the synthesis of neurotransmitter acetylocholine. It also takes part in the reaction
of detoxication, including the removal of some drugs, and in chelation of iron [26].
L-carnitine is synthesized in the liver, kidneys and brain from essential amino acids lysine and
methionine, with participation of the vitamins C, B6, PP, and iron. The main source of L-
carnitine in the diet is meat and dairy products. When the diet is rich in the aforementioned
products and there are no liver and kidney diseases, the risk of carnitine deficiency is low.
Bioavailability of carnitine from medical preparations is only ca. 20% [27].
Carnitine deficiency can result from fatty acid oxidation disorders, organic acidemias, renal
insufficiency, and treatment with some drugs, as valproic acid. The clinical symptoms of L-
carnitine deficiency involve brain with enhanced risk of hypoketonic-hypoglycemic and
hepatic encephalopathy, or skeletal and cardiac myopathy. Carnitine deficiency in case of fatty
acids oxidative disorders can cause epileptic seizures. The seizures may result from cerebral
bioenergetic failure associated with acute episodes of hypoglycemic, hypoketotic encephal‐
opathy, or hypoxic-ischemic encephalopathy due to cardiac arrhythmias and/or cardiomyop‐
athy [28].
In numerous studies, reduced carnitine levels were found during VPA therapy, especially with
prolonged use and with high dosage levels [29]. The mechanism of this may include: 1) the
formation of valproylcarnitine, 2) the reduction of tubular reabsorption of carnitine in the
kidneys, 3) the inhibition of selected enzymes, which take part in biosynthesis of carnitine, 4)
the inhibition of the membrane carnitine transporter and 5) the impairment of recycling of
carnitine from long-chain acylcarnitines by the VPA-induced decrease of mitochondrial free
Co-A level. Deficiency of carnitine is one possible mechanism which explains the VPA induced
hepatotoxity. Carnitine depletion can impair the urea cycle (by influence on its enzymes) and
cause accumulation of ammonia, what can be found in hepatic failure [30]. The impairment of
beta-oxidation can shift the metabolism of VPA toward predominantly peroxisomal gamma-
oxidation, resulting in excessive production and accumulation of toxic metabolite 4-en-VPA.
It is postulated that carnitine supplementation may increase the beta-oxidation of VPA and
limit production of its toxic metabolites. Carnitine inhibits free radicals generation preventing
the impairment of fatty acid betaoxidation in mitochondria and protects tissues from damage
by repairing oxidized membrane lipids [31].
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5. New therapeutic approaches
Some of side effects of therapy with VPA have been suggested by alteration the homeostasis
of trace elements and antioxidants. Seriously increase membrane lipid peroxidation at the
expense of protective antioxidants; this may lead to an increase in the frequency of seizures
and an idiosyncratic drug effect.
Adequate trace elements and antioxidants supply is essential for normal brain functions, and
is particularly important for protection against neurological disorders. To elucidate the
mechanism of action such substances in the brain should result in new safe therapeutic
approaches.
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